You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 9,309,244

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,309,244

Title:	Compound useful for the treatment of degenerative and inflammatory diseases
Abstract:	A novel compound able to inhibit JAK is disclosed, that comprises a compound according to Formula I: ##STR00001## or a pharmaceutically acceptable salt thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.
Inventor(s):	Menet; Christel Jeanne Marie (Mechelen, BE), Smits; Koen Kurt (Boechout, BE)
Assignee:	GALAPAGOS NV (Mechelen, BE)
Application Number:	14/677,058
Patent Claims:	1. A method for the treatment of psoriasis, comprising administering an amount of a compound according to Formula I: ##STR00031## or a pharmaceutically acceptable salt thereof sufficient to effect said treatment. 2. The method according to claim 1, wherein the compound is administered in combination with one or more further therapeutic agents selected from agents for the treatment of psoriasis. 3. The method according to claim 2, wherein the compound is administered in combination with one further therapeutic agent selected from agents for the treatment of psoriasis. 4. A method for the treatment of psoriasis, comprising administering an amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound according to Formula I: ##STR00032## or a pharmaceutically acceptable salt thereof, sufficient to effect said treatment. 5. A method for the treatment of psoriasis, comprising administering an amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier, a pharmaceutically effective amount of a compound according to Formula I: ##STR00033## or a pharmaceutically acceptable salt thereof, and a further therapeutic agent, sufficient to effect said treatment. 6. The method according to claim 4, wherein the pharmaceutical composition is administered in combination with one or more further therapeutic agents selected from agents for the treatment of psoriasis. 7. The method according to claim 6, wherein the pharmaceutical composition is administered in combination with one further therapeutic agent selected from agents for the treatment of psoriasis. 8. The method according to claim 5, wherein the further therapeutic agent is an agent for the treatment of psoriasis. 9. The method according to claim 2, wherein the further therapeutic agent is selected from topical agents selected from coal tar, dithranol, corticosteroids, vitamin D.sub.3 analogues, and retinoids; and systemic agents selected from synthetic disease modifying, immunomodulatory agents, and biological disease modifying, immunomodulatory agents. 10. The method according to claim 3, wherein the further therapeutic agent is selected from topical agents selected from coal tar, dithranol, corticosteroids, vitamin D.sub.3 analogues, and retinoids; and systemic agents selected from synthetic disease modifying, immunomodulatory agents, and biological disease modifying, immunomodulatory agents. 11. The method according to claim 6, wherein the further therapeutic agent is selected from topical agents selected from coal tar, dithranol, corticosteroids, vitamin D.sub.3 analogues, and retinoids; and systemic agents selected from synthetic disease modifying, immunomodulatory agents, and biological disease modifying, immunomodulatory agents. 12. The method according to claim 7, wherein the further therapeutic agent is selected from topical agents selected from coal tar, dithranol, corticosteroids, vitamin D.sub.3 analogues, and retinoids; and systemic agents selected from synthetic disease modifying, immunomodulatory agents, and biological disease modifying, immunomodulatory agents. 13. The method according to claim 8, wherein the further therapeutic agent is selected from topical agents selected from coal tar, dithranol, corticosteroids, vitamin D.sub.3 analogues, and retinoids; and systemic agents selected from synthetic disease modifying, immunomodulatory agents, and biological disease modifying, immunomodulatory agents. 14. The method according to claim 9, wherein the further therapeutic agent is selected from methotrexate, cyclosporine, retinoids, tioguanine, hydroxyurea, sulfasalazine, mycophenolate mofetil, azathioprine, tacrolimus, fumaric acid esters, and Amevive .TM., Enbrel .TM., Humira .TM., Remicade .TM., Raptiva .TM. and ustekinumab. 15. The method according to claim 10, wherein the further therapeutic agent is selected from methotrexate, cyclosporine, retinoids, tioguanine, hydroxyurea, sulfasalazine, mycophenolate mofetil, azathioprine, tacrolimus, fumaric acid esters, and Amevive .TM., Enbrel .TM., Humira .TM., Remicade .TM., Raptiva .TM. and ustekinumab. 16. The method according to claim 11, wherein the further therapeutic agent is selected from methotrexate, cyclosporine, retinoids, tioguanine, hydroxyurea, sulfasalazine, mycophenolate mofetil, azathioprine, tacrolimus, fumaric acid esters, and Amevive .TM., Enbrel .TM., Humira .TM., Remicade .TM., Raptiva .TM. and ustekinumab. 17. The method according to claim 12, wherein the further therapeutic agent is selected from methotrexate, cyclosporine, retinoids, tioguanine, hydroxyurea, sulfasalazine, mycophenolate mofetil, azathioprine, tacrolimus, fumaric acid esters, and Amevive .TM., Enbrel .TM., Humira .TM., Remicade .TM., Raptiva .TM. and ustekinumab. 18. The method according to claim 13, wherein the further therapeutic agent is selected from methotrexate, cyclosporine, retinoids, tioguanine, hydroxyurea, sulfasalazine, mycophenolate mofetil, azathioprine, tacrolimus, fumaric acid esters, and Amevive .TM., Enbrel .TM., Humira .TM., Remicade .TM., Raptiva .TM. and ustekinumab.

Details for Patent 9,309,244

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998	⤷ Try a Trial	2029-06-26
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998	⤷ Try a Trial	2029-06-26
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999	⤷ Try a Trial	2029-06-26
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004	⤷ Try a Trial	2029-06-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.